But, Ozempic is only one of many medications in a class known as GLP-1 agonists
Indeed, while progressive overload remains foundational to resistance training, but initial intensities should typically be low to moderate (e.g., 40%60% of 1RM) with gradual increases to minimize injury risk (Paluch et al., 2024)
However, long-term safety data for multi-peptide neuropathy protocols does not exist, and individual responses vary
GLP-1 medications have gained attention for their role in managing type 2 diabetes and supporting weight loss when prescribed by a healthcare professional
To put this in perspective, to justify their current valuation, they only have to grow their topline by ~7% for eight years while the overall obesity care market is expected to grow by ~26% CAGR